NeuroPace says FDA deems epilepsy label expansion filing not approvable in current form

• FDA told NeuroPace its PMA panel-track supplement to expand RNS into drug-resistant idiopathic generalized epilepsy is not approvable as filed.
• Agency requested additional clinical evidence from the NAUTILUS trial, including more data and context on patient populations, plus supporting literature.
• Company plans to file a Submission Issue Request to align on an amendment strategy, signaling a likely delay to any label expansion decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-321083), on July 28, 2026, and is solely responsible for the information contained therein.